EC Number |
Application |
Reference |
---|
3.4.21.110 | medicine |
acts as a potential invasin of group A streptococcus and promotes invasion independent of fibronectin |
673973 |
3.4.21.110 | medicine |
encapsulated C5a peptidase elicites significant immune responses and protection against group B streptococci challenge. C5a peptidase microsphere encapsulation has potential as a group B streptococci vaccine |
684315 |
3.4.21.110 | medicine |
encapsulated C5a peptidase elicits significant immune responses and protection against a group B Streptococcus challenge. C5a peptidase poly(lactide-coglycolide) microsphere encapsulation has potential as a group B Streptococcus vaccine |
717065 |
3.4.21.110 | medicine |
fibronectin adhesin activity of scpB plays a role in virulence |
-, 687071 |
3.4.21.110 | medicine |
immunization with C5a peptidase protein from either group A or group B streptococci provides protection against group A streptococcus infections in mice, moreover, mice immunized with antibodies directed against protein from group B streptococci also cleared streptococci from their lungs more efficiently than those immunized with tetanus toxoid |
677242 |
3.4.21.110 | medicine |
inactivates recombinant chemotaxin C5a by destroying its capacity to interact with the C5a receptor on human polymorphonuclear leukocytes |
671820 |
3.4.21.110 | medicine |
inactive mutant H193A elicits high titers of antigen-specific IgG1 antibodies and robust T cell-mediated immunities in mice showing potential as a Streptococcus vaccine. Cconjugating the trisaccharide repeating unit of Streptococcus polysaccharide with mutant H193A converts the nonimmunogenic oligosaccharide into a highly active and T cell-dependent antigen |
755385 |
3.4.21.110 | medicine |
increased anti-SCPA IgG levels in rheumatic fever, rheumatic heart disease and acute glomerulo nephritis cases. The rise of anti-SCPA IgG observed in patients is irrespective of different emm types of group A streptococci strains isolated from these patients. Indian females show higher concentration of anti-SCPA antibodies than male patients. Anti-SCPA IgG1 and anti-SCPA IgG3 are the predominant subclasses of anti-SCPA antibody and clearly distinguish individuals with acute rheumatic fever from those free of streptococcal disease |
687103 |
3.4.21.110 | medicine |
intranasal immunization with SCPA prevents colonization and infection of human tonsils, thereby eliminating potential reservoirs that maintain endemic disease |
673982 |
3.4.21.110 | medicine |
SCPA is highly immunogenic in children infected with group A streptococcal pharyngitis |
673974 |